3Guideline on non-clinical and clinical development of medical products for the prevention of nausea and vomiting associated with cancer chemotherapy [ C ]. European Medicine Agency ,2006,2-9
4Jorn Herrstedt. The MASCC Evidence Based Clinical Guidelines for Antiemesis [ C]. UICC World Cancer Congress, 2006,29-30
5Kris MG, Hesketh PJ, Somerfield MR et al. American Society of Clinical Oncology guideline for antiemetics in oncology : Update 2006 [ J ]. Clin 0ncol,2006, 24( 18 ) :2932-2947
6Roila F,Hesketh PJ,Herrstedt J, et al. Prevention of chemotherapy-and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetie Consensus Conference [ J ]. Ann Oncol,2006,17 ( 1 ) : 20-28
7NCCN Clinical Practice Guidelines in Oncology : Antiemesis, V. 1. 2007 [ S ]. 1
8Jordan K, Hinke A,Grothey A, et al. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis [J]. Support Care Cancer,2007,15 : 1023-1033
9Schmoll HJ, Aapro MS, Poli-Bigelli S, et al. Comparison of an aprepitant regimen with a multiple-day ondansetren regimen, both with dexamethasone, for antiemetic efficacy in high-dose eisplatin treatment [J]. Ann Oncol, 2006, 17 (6) :1000-1006
